4D Pharma PLC (LBPS)

US35085K1097 - ADR

1.65  +0.04 (+2.48%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to LBPS. LBPS was compared to 198 industry peers in the Pharmaceuticals industry. LBPS has a bad profitability rating. Also its financial health evaluation is rather negative. LBPS is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

LBPS had negative earnings in the past year.
LBPS had negative earnings in each of the past 5 years.
In the past 5 years LBPS always reported negative operating cash flow.

1.2 Ratios

Industry RankSector Rank
ROA -125.66%
ROE N/A
ROIC -55.1%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

LBPS does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -10376.92%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

LBPS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
LBPS has more shares outstanding than it did 1 year ago.
LBPS has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -8.18, we must say that LBPS is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 0.42 indicates that LBPS is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF N/A
Altman-Z -8.18
ROIC/WACC-5.29
WACC10.41%

2.3 Liquidity

LBPS has a Current Ratio of 5.21. This indicates that LBPS is financially healthy and has no problem in meeting its short term obligations.
LBPS has a Quick Ratio of 5.16. This indicates that LBPS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 5.21
Quick Ratio 5.16

More info and screens

0

3. Growth

3.1 Past

LBPS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.21%.
The Revenue has decreased by -3.70% in the past year.
EPS 1Y (TTM)-43.21%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q67.97%
Revenue 1Y (TTM)-3.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q11.54%

3.2 Future

Based on estimates for the next years, LBPS will show a decrease in Earnings Per Share. The EPS will decrease by -0.36% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.11%
EPS Next 2Y-10.93%
EPS Next 3Y-11.78%
EPS Next 5Y-0.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LBPS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LBPS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.99

4.3 Compensation for Growth

A cheap valuation may be justified as LBPS's earnings are expected to decrease with -11.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.93%
EPS Next 3Y-11.78%

More info and screens

0

5. Dividend

5.1 Amount

LBPS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

4D Pharma PLC

NASDAQ:LBPS (6/24/2022, 7:00:03 PM)

1.65

+0.04 (+2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap37.19M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.66%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) -10376.92%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 5.21
Quick Ratio 5.16
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-43.21%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-7.11%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-3.7%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y